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g/10.1016Abstract Tolerability is an essential part of drug therapy and can affect health and economic out-
comes. Withdrawal due to adverse reactions of medicines or lack of effectiveness is a major concern
in long-term treatments that inﬂuences cost-effectiveness analysis. In case of possibility of stopping
and switch to other interventions in decision analysis model, overhead costing may affect results
and decision-making processes. Thus, modifying of classic decision analysis model seems to be nec-
essary in such cases. My hypothesis is that by the use of a new decision model that can make links
between different Markov-like models accurate cost calculation could be achieved. The appearance
of model is going to be like a semicycle net. Considering the probability of switching from one treat-
ment strategy to another, one could give more precise economic evaluation results. In the ﬁrst step,
this model needs to be tested and compared with the conventional model. In the second step, the
impact of these differences has to be examined in the practical ﬁeld of health, drug policy and sup-
ply management. By applying this new decision model in total health budget, threshold and its con-
sequences on national health accounts and share of health in gross domestic product should be
tested.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license. Introduction
Economic evaluations are now used in many countries as a tool
for decision making for the assessment of new pharmaceuticals,il.com
niversity of Medical Sciences. Pub
h/
/j.jmhi.2012.03.008medical devices or procedures [1,2]. New health technologies
are more cost consuming [3,4]. This progress has highlighted
the importance of improvement in methodological aspects of
health economic evaluations and pharmacoeconomics.lished by Elsevier Ltd. Open access under CC BY-NC-ND license. 
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Figure 1 Decision analysis modeling for health interventions when switching is possible.
A new model for decision analysis in economic evaluations of switchable health interventions 13Management of health-care budget is essential for the most
important goals of health policy which are efﬁciency and equity
[5].
In its simplest form, economic evaluations compare two-
treatment strategies against each other regarding expected costs
and expected health outcomes [6]. Economic evaluations of
health-care interventions are usually based on data from a single
randomised controlled trial (RCT) or use decision analytic mod-
elling [6,7]. Economic evaluations based on decision analytic
modelling are an alternative to trial-based economic evaluations.
The use of decision analytic models in economic evaluations is
the only framework that has the potential tomeet all the require-
ments for economic evaluation for decision making [8].
The two most prominent model types are decision trees and
Markov models [6,8–10].
Markov model is particularly useful when a decision prob-
lem involves a risk that is ongoing over time. The model as-
sumes that the patient is always in one of a ﬁxed number of
states of health referred to as Markov states. All events of
interest are modelled as transitions from one state to another.
The time horizon of the analysis is divided into equal incre-
ments of time, referred to as Markov cycles. During each cycle,
the patient may make a transition from one state to another.
The Markov process is completely deﬁned by the probability
distribution among the starting states and the probabilities
for the individual allowed transitions. For a Markov model
of n states, there will be n2 transition probabilities. It is as-
sumed that a patient in a given state can make only a single-
state transition during a cycle [11]. Markov states are usually
well-being or ﬁrst step of illness especially in chronic diseases,progress on disease condition and ﬁnally death that is com-
monly considered as the absorption state [12,13].
In addition, tolerability is an essential part of drug therapy
that interferes with health-related outcomes [14]. Withdrawal
due to side effects of medicines or lack of effectiveness in
long-term treatments may have a great impact in cost-effec-
tiveness analysis [15]. In case of probability of switching to
other drugs in decision analysis model, overhead costing may
affect results and decision-making processes. Thus, modifying
of classic Markov model seems to be necessary when switch-
able drugs are compared with each other.
The hypothesis
My hypothesis is that by the use of a new decision model that
can make links between different Markov-like models accurate
cost calculation could be achieved. The appearance of model is
going to be like a semicycle net. Considering the probability of
switching from one treatment strategy to another, one could
give more precise economic evaluation results.
In this new model (Fig. 1), n state model will have
½n2 þ ðm 1Þðm1Þ transition possibilities where m is the num-
ber of treatment strategies that will be evaluated. Mandatory
assumption in this model is to identify the reason for with-
drawal from one treatment and switching to the other one.
The evaluation of hypotheses
In the ﬁrst step, this model needs to be tested and compared
with the conventional model. The difference of cost per events
14 S. Nikfarincluding health outcomes and quality adjusted life years
(QALYs) and incremental cost-effectiveness ratio (ICER)
should be assessed and its signiﬁcance and importance must
be evaluated. In the second step, the impact of these differences
has to be examined in the practical ﬁeld of health, drug policy
and supply management. Finally, the effect of applying this
new decision model in total health budget, threshold and its
consequences on national health accounts (NHA) and share
of health in gross domestic product (GDP) should be tested.
Discussion
In many countries, medicines represent the largest household
health expenditure [16]. Pharmaceuticals have made an impor-
tant contribution to global reductions in morbidity and mor-
tality [17]. Existence of a good structure and process for
ﬁnancing in drug supply helps to achieve the most important
aims of health managements including efﬁciency and equity
in access [18].
To date, health policymakers have tried many tools to make
more reliable and transparent decisions. One of these tools is to
use modelling in economic evaluations [19]. Epidemiologic
transition is responsible for increasing the prevalence of chronic
disease and increasing the well-being expectancy that are
accountable by incidence of new costly treatment diseases
[12]. The increase in health-related problems in parallel the
pharmaceutical market is emerging to solve the problem [20].
New medicines are usually more expensive than conventional
medicines because of reliance on high technologies. Drugs such
as antibiotics that were thought to be useful in short-term treat-
ment are newly applied for chronic illnesses such as inﬂamma-
tory bowel disease or irritable bowel syndrome [21–24]. Thus,
apart from volume of drug treatments that is increasing day
to day, their value is also growing [20,25,26], and all these have
highlighted the importance of accurate models for analysing
and making decision on economics aspects, and considering
opportunity costs. On the other hand, very close effectiveness
of such medicine to placebo or even their ineffectiveness neces-
sitates clariﬁcation by meta-analyses [27–30]. The use of models
that could better demonstrate risks and beneﬁt of different
interventions over time would take a special place in the ﬁeld
of pharmacoeconomics. The importance of this new model is
its capability to reveal the problem of stopping and switching
to other almost same interventions and evaluating its effect
on cost of comparative treatments.
The major complication of this model might be the infor-
mation problem. Follow-up of clinical cohorts for long time
would be difﬁcult and costly because ﬁnding the exact reasons
of switching is affected by the model. Also, sometimes switch-
ing or stopping is not because of effectiveness or side effects
and thus such problems can arise because of economic prob-
lems of patients that would affect the willingness to pay as
the major concern of health economists [12]. At last, shortage
of drugs due to lack of good management supply of gover-
nance and accessibility apprehensions [31,32] should be consid-
ered as a bias for data gathering of this model.
Conclusion
Implementing of this new model in decision analysis can lead
to robust results of cost-effectiveness and increase the accuracy
of decision making in different levels of health policies.Conﬂict of interest statement
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What do we already know about the subject?
Economic evaluations are now used in many countries
as a tool for decision making to assess new pharmaceuti-
cals, medical devices or procedures to control and manage
the health-care budget to reach efﬁciency and equity.
Economic evaluations compare at least two-treatment
strategies against each other regarding expected costs and
expected health outcomes. These are usually based on
data from a single RCT. Decision analytic modelling is
an alternative to trial-based economic evaluations. The
use of decision analytic models in economic evaluations
is the only framework that has the potential to meet all
the requirements for economic evaluation of decision
making. The two most prominent model types are deci-
sion trees and Markov models. Markov models are partic-
ularly useful when a decision problem involves a risk that
is ongoing over time.
What does your proposed theory add to the current
knowledge available, and what beneﬁts does it have?
Tolerability is an essential part of drug therapy that
interferes with health-related outcomes. In addition, with-
drawal and switching due to side effects of medicines or
lack of effectiveness could change economic evaluations
results. Probability of switching to other drugs in decision
analysis models would help estimate the exact cost of
interventions particularly in long-term treatments.
Among numerous available studies, what special further
study is proposed for testing the idea?
Results that will be obtained from this model need
testing and comparison with conventional models. Their
differences in cost per events and incremental cost-effec-
tiveness ratio should be assessed. Also, its signiﬁcance
and importance must be evaluated. Evaluation of the im-
pact of these differences in the practical ﬁeld of health and
drug policy, and supply management is necessary. The
outcome of implementing this new decision analysis mod-
el in total health budget, its threshold and consequences
on national health accounts, and share of health in gross
domestic product should be tested.References
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